Regeneron Pharmaceuticals stock rises 2.67% in strong market session
Updated
Updated · MarketWatch · May 6
Regeneron Pharmaceuticals stock rises 2.67% in strong market session
10 articles · Updated · MarketWatch · May 6
Shares closed at $721.05 on Wednesday as trading volume reached 738,420, above the 50-day average of 672,890.
The gain came as the S&P 500 rose 1.46% to 7,365.12 and the Dow Jones Industrial Average added 1.24% to 49,910.59.
Regeneron outpaced Amgen's 0.46% rise and Gilead's 2.11% gain, but trailed Moderna's 4.45% increase; the stock remains 12.19% below its January 9 52-week high of $821.11.
Will Regeneron's massive US R&D commitment under its new government pricing deal secure future growth or cap its profitability?
With new drug approvals, is Regeneron successfully diversifying before its blockbuster drugs face major competition?
Regeneron is offering a new gene therapy for free. What is the real business strategy behind this unprecedented move?